Mostrar el registro sencillo del ítem
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
dc.creator | Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., Bhatia C., Garrett D., Cotte C., Isaacs S., Gugerty E., Davidson A., Marder G.S., Schnitzer A., Goldberg B., McGinn T., Davidson K.W., Barish M.A., Qiu M., Zhang M., Goldin M., Matsagkas M., Arnaoutoglou E., Spyropoulos A.C. | en |
dc.date.accessioned | 2023-01-31T07:41:57Z | |
dc.date.available | 2023-01-31T07:41:57Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1182/blood.2020010529 | |
dc.identifier.issn | 00064971 | |
dc.identifier.uri | http://hdl.handle.net/11615/72328 | |
dc.description.abstract | Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether the risk extends postdischarge has been controversial. Our prospective registry included consecutive patients with COVID-19 hospitalized within our multihospital system from 1 March to 31 May 2020. We captured demographics, comorbidities, laboratory parameters, medications, postdischarge thromboprophylaxis, and 90-day outcomes. Data from electronic health records, health informatics exchange, radiology database, and telephonic follow-up were merged. Primary outcome was a composite of adjudicated VTE, ATE, and all-cause mortality (ACM). Principal safety outcome was major bleeding (MB). Among 4906 patients (53.7% male), mean age was 61.7 years. Comorbidities included hypertension (38.6%), diabetes (25.1%), obesity (18.9%), and cancer history (13.1%). Postdischarge thromboprophylaxis was prescribed in 13.2%. VTE rate was 1.55%; ATE, 1.71%; ΑCM, 4.83%; and MB, 1.73%. Composite primary outcome rate was 7.13% and significantly associated with advanced age (odds ratio [OR], 3.66; 95% CI, 2.84-4.71), prior VTE (OR, 2.99; 95% CI, 2.00-4.47), intensive care unit (ICU) stay (OR, 2.22; 95% CI, 1.78-2.93), chronic kidney disease (CKD; OR, 2.10; 95% CI, 1.47-3.0), peripheral arterial disease (OR, 2.04; 95% CI, 1.10-3.80), carotid occlusive disease (OR, 2.02; 95% CI, 1.30-3.14), IMPROVE-DD VTE score ≥4 (OR, 1.51; 95% CI, 1.06-2.14), and coronary artery disease (OR, 1.50; 95% CI, 1.04-2.17). Postdischarge anticoagulation was significantly associated with reduction in primary outcome (OR, 0.54; 95% CI, 0.47-0.81). Postdischarge VTE, ATE, and ACM occurred frequently after COVID-19 hospitalization. Advanced age, cardiovascular risk factors, CKD, IMPROVE-DD VTE score ≥4, and ICU stay increased risk. Postdischarge anticoagulation reduced risk by 46%. © 2021 American Society of Hematology | en |
dc.language.iso | en | en |
dc.source | Blood | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107087397&doi=10.1182%2fblood.2020010529&partnerID=40&md5=b6bae471e685c1f903a15aaabd2d2c2b | |
dc.subject | acetylsalicylic acid | en |
dc.subject | anakinra | en |
dc.subject | antibiotic agent | en |
dc.subject | antithrombocytic agent | en |
dc.subject | antivirus agent | en |
dc.subject | apixaban | en |
dc.subject | argatroban | en |
dc.subject | betamethasone | en |
dc.subject | cangrelor | en |
dc.subject | clopidogrel | en |
dc.subject | dabigatran | en |
dc.subject | dexamethasone | en |
dc.subject | enoxaparin | en |
dc.subject | famotidine | en |
dc.subject | fondaparinux | en |
dc.subject | glucocorticoid | en |
dc.subject | heparin | en |
dc.subject | hydrocortisone | en |
dc.subject | hydroxychloroquine | en |
dc.subject | hydroxymethylglutaryl coenzyme A reductase inhibitor | en |
dc.subject | immunoglobulin | en |
dc.subject | methylprednisolone | en |
dc.subject | prasugrel | en |
dc.subject | prednisolone | en |
dc.subject | prednisone | en |
dc.subject | rivaroxaban | en |
dc.subject | sarilumab | en |
dc.subject | ticagrelor | en |
dc.subject | tocilizumab | en |
dc.subject | warfarin | en |
dc.subject | anticoagulant agent | en |
dc.subject | adult | en |
dc.subject | age | en |
dc.subject | all cause mortality | en |
dc.subject | anticoagulation | en |
dc.subject | arterial thromboembolism | en |
dc.subject | Article | en |
dc.subject | bleeding | en |
dc.subject | cancer patient | en |
dc.subject | cardiovascular risk factor | en |
dc.subject | carotid artery | en |
dc.subject | carotid artery obstruction | en |
dc.subject | chronic kidney failure | en |
dc.subject | comorbidity | en |
dc.subject | controlled study | en |
dc.subject | coronary artery disease | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | demography | en |
dc.subject | diabetes mellitus | en |
dc.subject | disease registry | en |
dc.subject | electronic health record | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | hospital discharge | en |
dc.subject | hospital mortality | en |
dc.subject | hospital patient | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | intensive care | en |
dc.subject | intensive care unit | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | malignant neoplasm | en |
dc.subject | medical history | en |
dc.subject | middle aged | en |
dc.subject | obesity | en |
dc.subject | outcome assessment | en |
dc.subject | peripheral occlusive artery disease | en |
dc.subject | prospective study | en |
dc.subject | risk factor | en |
dc.subject | scoring system | en |
dc.subject | thrombosis prevention | en |
dc.subject | venous thromboembolism | en |
dc.subject | aged | en |
dc.subject | complication | en |
dc.subject | register | en |
dc.subject | thromboembolism | en |
dc.subject | Aged | en |
dc.subject | Anticoagulants | en |
dc.subject | COVID-19 | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Patient Discharge | en |
dc.subject | Registries | en |
dc.subject | Risk Factors | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Thromboembolism | en |
dc.subject | Elsevier B.V. | en |
dc.title | Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |